158 related articles for article (PubMed ID: 19695315)
1. In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human.
Lavé T; Birnböck H; Götschi A; Ramp T; Pähler A
Toxicol Lett; 2009 Nov; 190(3):303-9. PubMed ID: 19695315
[TBL] [Abstract][Full Text] [Related]
2. Modelling of patient EMS exposure: translating pharmacokinetics of EMS in vitro and in animals into patients.
Lavé T; Paehler A; Grimm HP; Gocke E; Müller L
Toxicol Lett; 2009 Nov; 190(3):310-6. PubMed ID: 19695316
[TBL] [Abstract][Full Text] [Related]
3. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
4. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
Lutz WK
Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
[TBL] [Abstract][Full Text] [Related]
5. General 4-week toxicity study with EMS in the rat.
Pfister T; Eichinger-Chapelon A
Toxicol Lett; 2009 Nov; 190(3):271-85. PubMed ID: 19442710
[TBL] [Abstract][Full Text] [Related]
6. EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.
Müller L; Singer T
Toxicol Lett; 2009 Nov; 190(3):243-7. PubMed ID: 19857794
[TBL] [Abstract][Full Text] [Related]
7. EMS in Viracept--initial ('traditional') assessment of risk to patients based on linear dose response relations.
Gocke E; Müller L; Pfister T
Toxicol Lett; 2009 Nov; 190(3):266-70. PubMed ID: 19439165
[TBL] [Abstract][Full Text] [Related]
8. Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate.
Gocke E; Bürgin H; Müller L; Pfister T
Toxicol Lett; 2009 Nov; 190(3):254-65. PubMed ID: 19857796
[TBL] [Abstract][Full Text] [Related]
9. What happened: the chemistry side of the incident with EMS contamination in Viracept tablets.
Gerber C; Toelle HG
Toxicol Lett; 2009 Nov; 190(3):248-53. PubMed ID: 19857795
[TBL] [Abstract][Full Text] [Related]
10. In vivo genotoxicity of EMS: statistical assessment of the dose response curves.
Gocke E; Wall M
Toxicol Lett; 2009 Nov; 190(3):298-302. PubMed ID: 19857797
[TBL] [Abstract][Full Text] [Related]
11. Measurement of the hemoglobin N-(2-oxoethyl)valine adduct in ethyl carbamate-treated mice.
Cai J; Myers SR; Hurst HE
Toxicol Appl Pharmacol; 1995 Mar; 131(1):73-9. PubMed ID: 7878680
[TBL] [Abstract][Full Text] [Related]
12. MNT and MutaMouse studies to define the in vivo dose response relations of the genotoxicity of EMS and ENU.
Gocke E; Ballantyne M; Whitwell J; Müller L
Toxicol Lett; 2009 Nov; 190(3):286-97. PubMed ID: 19446969
[TBL] [Abstract][Full Text] [Related]
13. The Viracept-EMS case: impact and outlook.
Walker VE; Casciano DA; Tweats DJ
Toxicol Lett; 2009 Nov; 190(3):333-9. PubMed ID: 19866516
[TBL] [Abstract][Full Text] [Related]
14. In vivo studies in the mouse to define a threshold for the genotoxicity of EMS and ENU.
Gocke E; Müller L
Mutat Res; 2009 Aug; 678(2):101-7. PubMed ID: 19376265
[TBL] [Abstract][Full Text] [Related]
15. Adducts of N-terminal valines in hemoglobin with isoprene diepoxide, a metabolite of isoprene.
Fred C; Cantillana T; Henderson AP; Golding BT; Törnqvist M
Rapid Commun Mass Spectrom; 2004; 18(18):2177-84. PubMed ID: 15378724
[TBL] [Abstract][Full Text] [Related]
16. Considerations regarding a permitted daily exposure calculation for ethyl methanesulfonate.
Müller L; Gocke E
Toxicol Lett; 2009 Nov; 190(3):330-2. PubMed ID: 19857798
[TBL] [Abstract][Full Text] [Related]
17. Trace determination of ethyl methanesulfonate in Viracept 250 mg tablets by gas chromatography-mass spectrometry.
Rebiere H; Maggio AF; Gimeno P; Levaillant D; Civade C; Bonnet PA; Tissier MH
Pharmeur Sci Notes; 2008 Feb; 2008(1):17-20. PubMed ID: 18430402
[TBL] [Abstract][Full Text] [Related]
18. Formation of hemoglobin and albumin adducts of benzene oxide in mouse, rat, and human blood.
Lindstrom AB; Yeowell-O'Connell K; Waidyanatha S; McDonald TA; Golding BT; Rappaport SM
Chem Res Toxicol; 1998 Apr; 11(4):302-10. PubMed ID: 9548800
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
[TBL] [Abstract][Full Text] [Related]
20. Toxicokinetics of bisphenol A in rats, monkeys and chimpanzees by the LC-MS/MS method.
Tominaga T; Negishi T; Hirooka H; Miyachi A; Inoue A; Hayasaka I; Yoshikawa Y
Toxicology; 2006 Sep; 226(2-3):208-17. PubMed ID: 16914249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]